{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:36:14Z","timestamp":1781642174188,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.cllc.2017.07.002","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:47:19Z","timestamp":1502326039000},"page":"e247-e252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non\u2013small-cell Lung Cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"Takahisa","family":"Kawamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0590-9259","authenticated-orcid":false,"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Wakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Omae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tanigawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Ohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2017.07.002_bib1","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2017.07.002_bib2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2017.07.002_bib3","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2017.07.002_bib4","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.07.002_bib5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lungcan.2014.08.016","article-title":"Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)","volume":"86","author":"Chouaid","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.07.002_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2014.03.016","article-title":"Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients","volume":"85","author":"Kuiper","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.07.002_bib7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/cas.12963","article-title":"Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure","volume":"107","author":"Kawamura","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2017.07.002_bib8","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1186\/s12885-016-2902-0","article-title":"Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients","volume":"16","author":"Ko","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2017.07.002_bib9","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2017.07.002_bib10","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2017.07.002_bib11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2017.07.002_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.lungcan.2015.10.004","article-title":"EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291","volume":"90","author":"Thress","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.07.002_bib13","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/1078-0432.CCR-15-1260","article-title":"Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686)","volume":"22","author":"Karlovich","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.07.002_bib14","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jtho.2016.05.035","article-title":"A\u00a0highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma","volume":"11","author":"Reckamp","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.07.002_bib15","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.07.002_bib16","doi-asserted-by":"crossref","first-page":"48059","DOI":"10.18632\/oncotarget.10351","article-title":"The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M","volume":"7","author":"Tseng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2017.07.002_bib17","doi-asserted-by":"crossref","first-page":"36458","DOI":"10.1038\/srep36458","article-title":"Association of EGFR exon 19 deletion and EGFR-TKI treatment duration with frequency of T790M mutation in EGFR-mutant lung cancer patients","volume":"6","author":"Matsuo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2017.07.002_bib18","doi-asserted-by":"crossref","first-page":"90ra59","DOI":"10.1126\/scitranslmed.3002356","article-title":"Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling","volume":"3","author":"Chmielecki","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cllc.2017.07.002_bib19","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/JTO.0000000000000647","article-title":"Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI","volume":"10","author":"Hata","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.07.002_bib20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cllc.2012.10.007","article-title":"Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib","volume":"14","author":"Park","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2017.07.002_bib21","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s10147-014-0761-8","article-title":"The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor","volume":"20","author":"Ko","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.cllc.2017.07.002_bib22","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1002\/cncr.28364","article-title":"Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations","volume":"119","author":"Hata","year":"2013","journal-title":"Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730417302103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730417302103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:08:52Z","timestamp":1761505732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730417302103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1525730417302103"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2017.07.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non\u2013small-cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2017.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}